...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy and asthma proceedings >The effects of repeat omalizumab administration on skin test positivity and the assessment of the safety of administration in patients with positive skin tests to mouse antigen.
【24h】

The effects of repeat omalizumab administration on skin test positivity and the assessment of the safety of administration in patients with positive skin tests to mouse antigen.

机译：omalizumab重复给药对皮肤测试阳性的影响以及对小鼠抗原皮肤测试阳性的患者的给药安全性评估。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Patients receiving omalizumab for moderate-to-severe allergic asthma were evaluated for the effect of omalizumab administration on immediate hypersensitivity skin test reactions. The existence of a relationship between a positive skin test for mouse antigen and risk for anaphylaxis in patients receiving omalizumab was also investigated. Seventeen patients were skin tested serially to tree, grass, and weed pollens; molds; dust mites; cat and dog allergens; mouse antigen; and cockroaches. Skin tests were performed before the initiation of omalizumab therapy and at each subsequent clinic visit (every 2-4 weeks). At the time of each visit, skin tests were performed immediately before the subcutaneous administration of omalizumab and 20 minutes afterward. A marked reduction in skin test reactivity was noted after the administration of omalizumab. Some of these reductions became more pronounced 20 minutes after administration compared with testing done before administration. There was one mild urticarial reaction 20 minutes after administration in a patient with a positive skin test to mouse antigen. The skin test was positive at the time of this reaction. Omalizumab therapy was continued without further adverse events and the skin test to mouse antigen became negative. In addition, seven other subjects with positive skin tests to mouse antigen have received repeated doses of omalizumab without adverse events. Omalizumab administration results in significant reduction of skin test reactivity to aeroallergens. Furthermore, a positive skin test to mouse antigen does not automatically preclude the use of omalizumab for therapy of moderate-to-severe allergic asthma.
机译：评估接受omalizumab治疗中至重度过敏性哮喘的患者对omalizumab给药对立即超敏性皮肤测试反应的影响。还研究了接受奥马珠单抗的患者的小鼠抗原皮肤试验阳性与过敏反应风险之间的关系。十七名患者接受了树木，草和杂草花粉的皮肤测试。模具尘螨;猫和狗的过敏原;小鼠抗原和蟑螂。在开始奥马珠单抗治疗之前和随后的每次临床访视（每2-4周）进行皮肤测试。每次访视时，立即在皮下给予奥马珠单抗之前和之后20分钟进行皮肤测试。服用奥马珠单抗后，皮肤测试反应性明显降低。与给药前进行的测试相比，给药后20分钟这些减少中的一些变得更加明显。给药后20分钟，对小鼠抗原皮肤试验阳性的患者出现轻度荨麻疹反应。该反应发生时皮肤试验为阳性。继续进行Omalizumab治疗，没有进一步的不良事件，对小鼠抗原的皮肤试验也呈阴性。另外，对小鼠抗原皮肤试验阳性的其他七名受试者已接受重复剂量的奥马珠单抗治疗，且无不良事件。奥马珠单抗的施用导致皮肤测试对气敏原的反应性显着降低。此外，对小鼠抗原的皮肤试验阳性并不自动排除使用奥马珠单抗治疗中度至重度过敏性哮喘的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号